Skip to content Skip to footer
Subscribe Now

NEWS

GSK to Acquire Nuvalent for ~$10.6B
Shots: GSK has entered an agreement to acquire Nuvalent, accelerating its entry into lung cancer As per the deal, GSK will acquire Nuvalent through a tender offer of $124 per share in cash, valuing the company at ~$10.6B (£8.0B); net of acquired cash, GSK’s total investment is estimated at $9.4B (£7.1B). Closing is expected in…
June 9, 2026
Johnson & Johnson to Acquire Firefly Bio for $1B
Shots: J&J has entered into a definitive agreement to acquire Firefly Bio, incl. its Firelink degrader antibody conjugate (DAC) platform, expanding its oncology pipeline As per the deal, J&J will acquire Firefly Bio for $1B in cash, with closing expected later this year The Firelink DAC platform is a targeted protein degradation tech that selectively…
June 9, 2026
Incyte to Acquire Vega Therapeutics for ~$2B
Shots: Incyte has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, to expand its hematology portfolio into bleeding disorders As per the deal, Incyte will acquire Vega for $1.25B upfront, with ~$750M in additional payments upon achievement of sales milestones Acquisition will expand Incyte’s hematology portfolio with…
June 8, 2026
Alvotech Reports US FDA BLA Acceptance of AVT16 (Biosimilar, Entyvio)
Shots: The US FDA has accepted BLA for AVT16, a biosimilar to Entyvio (vedolizumab) as a lyophilized vial for IV administration, to treat adults with mod. to sev. active ulcerative colitis & Crohn’s disease BLA is supported by analytical, PK, & immunogenicity data demonstrating biosimilarity between AVT16 & the reference product, plus Alvotech has filed a…
June 8, 2026
Nurix Therapeutics Inks ~$3B Deal with Roche to Advance Bexobrutideg
Shots: Nurix has entered a global collaboration with Roche to develop & commercialize bexobrutideg (PO), a BTK targeted protein degrader, which is under P-II/III trial for chronic lymphocytic leukemia Nurix will receive $700M upfront & ~$2.3B in milestones. Development costs will be shared (40% Nurix & 60% Roche), with both co-commercializing the drug & equally…
June 8, 2026
Load more